Myriad Genetics Inc. MYGN shares plunged 37.80% in Thursday’s after-hours session after the company reported second-quarter ...

Myriad Genetics partners with AWS to enhance Image Genius, speeding up document processing, and improving insurance workflows ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q2 CY2026, with sales falling 10.5% year on year to $190.7 million.

Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% ...

Myriad Genetics lowered its full-year revenue guidance, as second quarter sales fell due to volume challenges in prenatal health and increased payer friction. The genetic testing and precision ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second ...

Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging ...

Deep learning approaches have transformed how scientists predict the activity and function of DNA sequences in the genome. A ...

View SOPHiA GENETICS SA SOPH stock quote prices, financial information, real-time forecasts, and company news from CNN.

SOPHiA GENETICS President and CEO Ross Muken discusses the use of AI and technology in diagnosing and treating patients, ...

Good day, and thank you for standing by. Welcome to Myriad Genetics' Second Quarter 2026 Financial Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being ...

According to MarketsandMarkets, the Animal Genetics Market is projected to reach USD 9.37 billion by 2031 from USD 6.64 billion in 2026, at ...